Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)

Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)

354
Spira, AvrumBoston University
1) a multi-gene mRNA biomarker measured in cytologically normal large airway epithelial cells identified using genome-wide gene-expression profiling, 2) proteomic profiles measured in bronchial airway epithelial cells, 3) serum glycan antibody signature, 4) hypermethylated sites found in promoter regions of tumor suppressor genes measured in blood, 5) cytokines and growth factors secreted from the tumor microenvironment measured in peripheral blood, and 6) two distinct circulating miRNA signatures measured in the serum and plasma
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

The goal of this collaborative group study is to improve the diagnostic evaluation of patients with indeterminate pulmonary nodules by determining whether molecular biomarkers for lung cancer diagnosis, measured in minimally invasive and non-invasive biospecimens, are able to distinguish between patients with malignant or benign indeterminate pulmonary nodules that are incidentally detected on CT scan in high risk smokers. Achieving this goal would suggest that these biomarkers could also be applied in the setting of indeterminate pulmonary nodules that are detected as part of radiographic screening for lung cancer. Sensitive and specific biomarkers that discriminate between patients with malignant or benign indeterminate pulmonary nodules could spur early treatment and thereby improve lung cancer outcomes, while minimizing complications from diagnostic procedures in patients without lung cancer. Thus, this collaborative group proposal seeks to validate a series of molecular biomarkers (including mRNA, miRNA and proteomic signatures in the airway and blood) that have been developed by EDRN lung cancer investigators as effective diagnostic tools of lung cancer for patients with indeterminate pulmonary nodules

3.1.1   Aim 1 Establish a cohort (n=200) of current and former smokers with indeterminate pulmonary nodules (7mm-25mm) on whom clinical, radiographic and biospecimen repositories are developed and who are followed prospectively until final diagnosis. 3.1.2   Aim 2 Validate the diagnostic accuracy of existing molecular biomarkers in the airway and blood to detect lung cancer in this clinical cohort.
Airway gene-expression biomarker (BU) Airway protein biomarker (VU): LC-MRM-MS analyses Serum glycan biomarker (NYU): Plasma promoter methylation biomarker (JHU): Serum cytokines biomarker (UCLA): Serum/Plasma miRNA biomarker (OSU): Plasma miRNA biomarker (UMD):

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement